# Ares Management Corporation (ARES) — Financial Analysis

**Exchange:** NYSE  
**Coverage as of:** 2026-Q2  
**Updated:** 2026-05-28  
**Tier:** Free primer (step 2 of 19)  
**Sibling pages:** /stocks/ARES/thesis · /stocks/ARES/memo

## Financial Snapshot

---
ticker: ARES
step: 04
generated: 2026-05-28
source: coverage-next-full (transcript-free)
---

### ARES — Step 04: Financial Quality & Adversarial Sweep

#### Key Findings

ARES financial statements are **clean from an accounting-integrity standpoint** — no restatements in recent history, Big Four auditor (Ernst & Young) [S2], standard non-GAAP measures (FRE, RI, DE) clearly bridged to GAAP, segment disclosures comprehensive. **GAAP volatility is structural, not a quality concern** — Consolidated Funds (CLOs and AOG-consolidated entities) inflate the balance sheet by ~$20B+ and inject swing in operating income via fair-value mark adjustments [S3]. **Adversarial sweep is mild:** no active short reports specific to ARES, no SEC enforcement actions, no whistleblower allegations identified. The primary bear narrative is sector-wide — the **"$265B private credit meltdown" framing** (Fortune March 2026) [S11] which paints all alt managers (not just ARES) as overvalued/over-extended. **Watch items:** (a) insider open-market buying = 0 during the March 2026 drawdown, signaling neither conviction nor concern from management [S10]; (b) FY2025 FRE margin printed 41.7% — below the 43%+ peak in FY2023 [S2][S8], a small compression flag worth monitoring; (c) GCP step-up created **$3.4B of new goodwill + intangibles** in FY2025 [S3] — substantial PPA load to track for impairment over time. **Net neutral for thesis** — quality is solid but no positive surprises.

#### Implications for Thesis and Valuation

1. **Use non-GAAP FRE / DE / RI for valuation** — GAAP figures are not the right lens.
2. **Goodwill + intangibles surveillance** is a forward concern given the $3.4B GCP step-up; any FY2026/2027 impairment would be a meaningful negative signal.
3. **FRE margin compression watch** — the FY25 41.7% vs FY23 43%+ is small but bears monitoring; further compression below 40% would challenge thesis.
4. **No accounting reason to discount** the cited DE per share number — ARES has a multi-year track record of clean bridges between GAAP and non-GAAP.
5. **Adversarial sweep gives no specific bear** — but the sector-wide private-credit narrative remains a material macro overhang.

#### Objective

Test the quality of ARES's reported financials and conduct an adversarial sweep — short reports, lawsuits, regulatory actions, accounting irregularities — to surface any specific bear thesis the consensus may be missing.

#### Narrative Analysis

##### Earnings Quality

**Auditor:** Ernst & Young LLP — Big Four; no auditor changes recently [S2]. EY has audited ARES since at least 2014 IPO.

**Restatements:** None identified in the FY2023, FY2024, or FY2025 10-Ks.

**Internal controls:** Standard Section 404 certification by CEO Michael Arougheti and CFO Jarrod Phillips; no material weaknesses disclosed in FY2025 10-K [S2].

**Critical accounting estimates** (per 10-K):
1. Performance-fee recognition (revenue-recognition assumption on harvest timing)
2. Investments-at-fair-value classification (Level 3 inputs material)
3. Goodwill and intangibles impairment testing
4. Compensation expense estimation (carry-pool comp accruals)
5. Income tax provision (Up-C related TRA liability)

Each of these involves management judgment but is well-disclosed and follows industry-standard treatment.

##### GAAP vs Non-GAAP Bridge

ARES management directs investors to **Fee-Related Earnings (FRE)**, **Realized Income (RI)**, and **Distributable Earnings (DE)** as the primary economic measures, with full reconciliations to GAAP net income in the earnings releases [S4][S8] and 10-K [S2].

| Measure | FY2025 | What it is |
|---|---|---|
| GAAP Total Revenues | $4,756M | Includes management fees + perf fees + investment income + gross-ups |
| GAAP Net Income | $527M | Includes Consolidated Fund swings + non-cash items |
| Total Fee-Related Revenue (non-GAAP, segment) | ~$3,800M | Management fees + recurring fee streams |
| Fee-Related Earnings (FRE) | ~$2,005M (FY25 est) | Recurring management-fee-driven profitability |
| FRE Margin | 41.7% | Below FY23 43%+ peak; mild compression |
| Realized Income (RI) | ~$1,990M (FY25 est) | Including realized perf fees + Aspida income |
| Distributable Earnings (DE) | ~$1,640M | Cash basis ARES can distribute |
| DE per share | $4.97 | Per total economic interest share count |

GAAP-to-non-GAAP bridges in 10-K Note 19 (segment reporting) and earnings releases are clear and consistent quarter to quarter.

##### Consolidated Funds (the Single Biggest GAAP Distortion)

ARES is required to consolidate certain CLOs and investment vehicles where it has economic exposure that qualifies as a controlling financial interest under US GAAP. This adds approximately:
- **$20B+ of CLO loan investments** to assets
- **$15B+ of CLO notes** to liabilities
- **$4-5B of non-controlling-interest equity** (third-party LP capital)
- Quarter-to-quarter fair-value mark-to-market swings that inflate and deflate "revenues" and "expenses" symmetrically

This is why GAAP operating income was only **$47M FY2025** while the underlying economic earnings (DE) were **$1.64B** [S3][S2]. The 33× delta is entirely driven by Consolidated Funds gross-up — not a quality concern but a structural feature of asset-manager accounting.

##### Statement-Quality Adjustments (Material Items)

1. **Revenue recognition on performance fees** — recognized only when the realization event occurs (i.e., when the fund makes a distribution above the hurdle rate). Conservative. NAPI on balance sheet shows accrued-but-unrealized carry; this is real economic value not yet through the P&L.

2. **Performance-fee compensation expense** — paid out to deal-team carry-pool participants. ARES discloses this on a gross-up basis with the underlying performance income. Comp ratio ~50% [A10]. This is industry standard.

3. **Stock-based compensation** — ARES SBC ~$300-400M annually (Up-C structure compensates partners via various instruments). This is real economic expense and should be deducted from any "true" earnings calculation. ARES does NOT include SBC in DE, which is a fair criticism — but consensus and peers all use the same convention.

4. **Up-C / TRA structure** — Up-C corporate structure means ~25-30M AOG units are exchangeable into Class A shares; conversion triggers a Tax Receivable Agreement (TRA) liability obligating ARES to pay ~85% of resulting tax savings to historical AOG unitholders. This creates a cash leakage of ~$50-100M annually. Documented in MD&A but easy to miss in summary metrics [S2].

5. **Series B Mandatory Convertible Preferred** — ~$1.0B face value; converts to common shares in 2027 at a fixed price band. Adds ~3-4% dilution at conversion. Documented; not hidden [S5].

6. **Goodwill + intangibles step-up from GCP** — As noted, $3.4B incremental; subject to annual impairment testing. No impairment indicators at FY2025 close but worth tracking.

##### Adversarial Research Sweep

**Short reports:** None specific to ARES identified. Hindenburg, Muddy Waters, Spruce Point — none have published on ARES. Broader sector criticism exists (Fortune $265B private credit panic [S11], commentary by certain credit hedge funds questioning industry NAVs) but no firm-specific short report.

**SEC enforcement actions:** None against ARES or its officers in the past 5 years per EDGAR search.

**SEC private fund adviser rules:** The 2023 SEC private fund adviser rulemaking was largely **vacated by the 5th Circuit in mid-2024** [S15]. Remaining regulatory risk is modest.

**Lawsuits / litigation:** Routine industry litigation only — no material adverse outcomes per 10-K disclosures [S2]. Standard derivative suits, ERISA-related claims that have been resolved or are immaterial.

**Whistleblower / governance issues:** None identified.

**Insider trading scrutiny:** Programmatic 10b5-1 selling by founders (Ressler, Arougheti, Rosenthal, Kaplan) is ongoing and disclosed; no Form 4 anomalies or off-program sales suggesting non-public information advantage [S10].

**Activist short positions:** None reported in 13F filings or short-interest data; ARES short interest is low (~2-3% of float).

**Industry-wide bear narratives:**
- Fortune March 2026 "$265B private credit meltdown" — sector-wide [S11]
- Bain & Company, Bridgewater, certain credit hedge funds — generic NAV-questioning of private credit
- Citi research notes (referenced in news flow) — cautious on alternative manager multiples
- None of these are ARES-specific

##### Operating Cash Flow Quality

| Period | GAAP CFO | DE | Convergence Quality |
|---|---|---|---|
| FY2023 | -$233M | ~$1.5B | Wide divergence (Consolidated Funds + working capital) |
| FY2024 | $2,791M | ~$1.55B | CFO > DE (CLO inflows boosted CFO) |
| FY2025 | $3,267M | ~$1.64B | CFO > DE (similar pattern) |

CFO consistently exceeds DE in recent years because CLO note issuance and certain capital activities are reported as operating cash flow under GAAP. The economic-cash measure (DE) is more conservative — the right number for dividend-coverage analysis.

##### Dividend Coverage

Q1 2026 dividend: $1.35/sh × ~329.5M total economic shares ≈ $445M paid out.
Q1 2026 DE: ~$410M (extrapolated from RI/sh of $1.24) — **dividend slightly above DE for Q1 alone**.

This is consistent with management's quarterly dividend policy (constant or modestly rising per share) and the typical seasonality where Q4 is the high earnings quarter (carry-harvest weighted). On a trailing-12-month basis dividend coverage is ~110-115%, healthy but not generous. Watch for any year where DE coverage falls below 100%.

#### Evidence and Sources

- Auditor + clean restatement record: ARES 10-K FY2025 [S2]
- GAAP-to-non-GAAP bridges: 10-K Note 19 + each quarterly Ex 99.2 [S2][S4][S8]
- Consolidated Funds quantum: Q1 2026 10-Q balance sheet detail [S3]
- 5th Circuit vacatur of SEC private fund rules: industry coverage [S15]

#### Assumption Register Updates

No new assumptions added. A10 (perf-fee comp ratio ~50%) and A20 (DE/equity ~25-30%) already capture key estimates.

#### Tables and Calculations

See GAAP-vs-non-GAAP bridge table and cash flow convergence table above.

#### Open Questions and Data Gaps

1. **SBC on a DE basis** — ARES (like peers) excludes from DE; the "true" cash-economic return is somewhat lower than headline DE per share
2. **GCP impairment risk** — Watch for any indicators in FY2026/2027 10-K MD&A
3. **Performance-fee comp ratio** — Industry estimates ~50%; actual is not always cleanly disclosed
4. **Consolidated Funds expansion** — Will continue to scale with CLO platform growth; not a problem per se but inflates GAAP-vs-economic divergence

#### Next-Step Dependencies

Step 06 (balance sheet & dilution) deepens the analysis of goodwill, intangibles, debt, and per-share dilution. Step 07 (capital allocation) examines the GCP deal in detail. Step 13 (forecast under `/complete-coverage`) will model FRE margin trajectory — any compression below 40% would be a thesis revision trigger.

#### Source Index

| Tag | Document or URL | Section / Page / Slide | Date | Notes |
|---|---|---|---|---|
| [S2] | ARES 10-K FY2025 | Notes 2 (acctg policies), 19 (segment), MD&A | 2026-02-25 | Auditor, statements, bridges |
| [S3] | SEC XBRL companyfacts | Balance sheet line items | 2026-05-28 | Consolidated Funds quantum |
| [S4] | ARES Q1 2026 Ex 99.2 | Reconciliations pp 18-22 | 2026-05-01 | Quarterly GAAP→non-GAAP |
| [S5] | ARES 10-K FY2024 | Note 12 Preferred Stock | 2025-02-27 | Series B mandatory convertible |
| [S8] | ARES Q4 2025 release | FY25 FRE margin 41.7% | 2026-02 | Margin compression context |
| [S10] | SEC Form 4 + insider trackers | 12-month activity | 2026-05-28 | 0 open-market buys (March 2026 drawdown) |
| [S11] | Fortune | "$265B private credit meltdown" | 2026-03-14 | Sector-wide adversarial narrative |
| [S15] | AGM Alts Weekly + industry coverage | 5th Circuit vacatur | 2024-mid | SEC private fund rules vacated |

## Deeper Financial Analysis

The fundamental tier ($1.00) adds 8 dimensions not included here:

- Revenue Breakdown — segment revenue, geographic mix, product-line margins
- Financial Trends — QoQ momentum, leading indicators, inflection points
- Balance Sheet — debt structure, dilution risk, working capital dynamics
- Capital Allocation — ROIC, buyback cadence, reinvestment efficiency
- Earnings Analysis — beats/misses, guidance vs actuals, transcript highlights
- Competitive Positioning — market share, pricing power, peer benchmarks
- Industry Context — TAM, sector tailwinds/headwinds, regulatory backdrop

**API endpoint:** GET /api/v1/research/ARES/fundamental

## Navigation

- Overview: /stocks/ARES
- Financials (this page): /stocks/ARES/financials
- Thesis: /stocks/ARES/thesis
- Investment Memo: /stocks/ARES/memo
- Coverage universe: /stocks